Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.60 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | BCL6 | P41182 | 1/20 | 0.41 |
| ▸ | BCOR | Q6W2J9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3840607 | 0.85 | VCAM1 (0.64) | XDHVCAM1LMNAALDH1A1TSHR | |
| SCHEMBL73860 | 0.82 | VCAM1 (0.70) | XDHVCAM1LMNAALDH1A1TSHR | |
| Fluoride SCHEMBL28259583 | 0.81 | VCAM1 (0.68) | XDHVCAM1LMNAALDH1A1TSHR | |
| SCHEMBL82629 | 0.79 | VCAM1 (0.66) | XDHVCAM1LMNAALDH1A1TSHR | |
| SCHEMBL698847 | 0.79 | VCAM1 (0.66) | XDHVCAM1LMNAALDH1A1TSHR | |
| SCHEMBL2477528 | 0.78 | VCAM1 (0.74) | XDHVCAM1LMNAALDH1A1TSHR | |
| SCHEMBL1179904 | 0.78 | VCAM1 (0.59) | XDHVCAM1LMNAALDH1A1TSHR | |
| SCHEMBL361867 | 0.78 | VCAM1 (0.59) | XDHVCAM1LMNAALDH1A1TSHR | |
| SCHEMBL361541 | 0.78 | VCAM1 (0.59) | XDHVCAM1LMNAALDH1A1TSHR | |
| SCHEMBL1232789 | 0.78 | ALDH1A1 (0.60) | XDHVCAM1LMNAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057452-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | CATYLIX, INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057452-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | CATYLIX, INC. (US) | 2015-02-26 | — | — | US | disclosed |
| EP-2834216-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | Catylix Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| WO-2013152170-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | CATYLIX, INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013152170-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | CATYLIX, INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| US-7655689-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655689-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7517904-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517904-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-14 | — | — | US | disclosed |
| US-7470797-B2 | Fused heterocyclic imido and amido compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-20060223832-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-10-05 | — | — | US | disclosed |
| EP-1458723-A4 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050272799-A1 | Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2005-12-08 | — | — | US | disclosed |
| US-6953679-B2 | Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050192253-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050119228-A1 | METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | disclosed |
| CN-1589271-A | Fused heterocyclic succinimide compounds and analogs thereof as modulators of nuclear hormone receptor function | BRISTOL MYERS SQUIBB CO (US) | 2005-03-02 | — | — | CN | disclosed |
| EP-1458723-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristols-Myers Squibb Company (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| WO-2003062241-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119228-A1 | METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF | SUCNR1, SHBG, FSHR | XDH 2121/4885VCAM1 3648/4885LMNA 2602/4885 |
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | XDH 3201/4885VCAM1 3646/4885LMNA 3449/4885 |
| US-20060223832-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | XDH 3201/4885VCAM1 3646/4885LMNA 3449/4885 |
| US-20050192253-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | XDH 3201/4885VCAM1 3646/4885LMNA 3449/4885 |
| US-20050272799-A1 | Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | XDH 3201/4885VCAM1 3646/4885LMNA 3449/4885 |
| US-20150057452-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | XDH 4676/4885VCAM1 4181/4885LMNA 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.